Skip to content

CapEx at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$347M+33.5%
Eli Lilly logo
Eli LillyLLY
$2.33B+54.0%
Amgen logo
AmgenAMGN
$712M+73.2%
AbbVie logo
AbbVieABBV
$265M+12.8%
Incyte logo
IncyteINCY
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE

Other financials

Income statement

See full
Revenue$56.4M+99.0%
Operating income-$3.6M+81.1%
Net income$3.8M+132%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$193.7M+38.7%
Total debt$9.8M-13.9%
Total equity$655.5M-4.9%
Total assets$697.5M-6.0%

Cash flow

See full
Operating cash flow-$48.9M-139%
Free cash flow-$49.2M-139%

Valuation

See full
Market cap$7.26B+127%
Enterprise value$7.07B+130%
P/S98×+82.6×

Profitability

See full
Operating margin-192.4%-205pp
Net margin-154.9%-182pp
FCF margin-12,264.3%-12,527pp

Returns & leverage

See full
Return on equity-17.1%-26.1pp
Debt / equity0.0×
Current ratio17.8×+0.5×

Where this comes from

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's capex.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Protagonist Therapeutics's capex?
Protagonist Therapeutics (PTGX) reported capex of $215K in Q1 2026.
How has Protagonist Therapeutics's capex changed year-over-year?
Protagonist Therapeutics's capex decreased by 60.6% year-over-year, from $545K to $215K.
What is the long-term trend for Protagonist Therapeutics's capex?
Over 4 years (2021 to 2025), Protagonist Therapeutics's capex has grown at a 9.6% compound annual growth rate (CAGR), from $1.1M to $1.59M.
What does capex mean?
Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.